Skip to content
My WebMD Sign In, Sign Up

HIV & AIDS Health Center

Font Size

HIV-2

Who should be tested for HIV-2?

Because epidemiologic data indicate that the prevalence of HIV-2 in the United States is very low, CDC does not recommend routine HIV-2 testing at U.S. HIV counseling and test sites or in settings other than blood centers. However, when HIV testing is to be performed, tests for antibodies to both HIV-1 and HIV-2 should be obtained if demographic or behavioral information suggests that HIV-2 infection might be present.

Persons at risk for HIV-2 infection include

  • Sex partners of a person from a country where HIV-2 is endemic (refer to countries listed earlier)
  • Sex partners of a person known to be infected with HIV-2
  • People who received a blood transfusion or a nonsterile injection in a country where HIV-2 is endemic
  • People who shared needles with a person from a country where HIV-2 is endemic or with a person known to be infected with HIV-2
  • Children of women who have risk factors for HIV-2 infection or are known to be infected with HIV-2

HIV-2 testing also is indicated for

  • People with an illness that suggests HIV infection (such as an HIV-associated opportunistic infection) but whose HIV-1 test result is not positive
  • People for whom HIV-1 Western blot exhibits the unusual indeterminate test band pattern of gag (p55, p24, or p17) plus pol (p66, p51, or p32) in the absence of env (gp160, gp120, or gp41)

Among all HIV-infected people, the prevalence of HIV-2 is very low compared with HIV-1. However, the potential risk for HIV-2 infection in some populations (such as those listed) may justify routine HIV-2 testing for all people for whom HIV-1 testing is warranted. The decision to implement routine HIV-2 testing requires consideration of the number of HIV-2-infected persons whose infection would remain undiagnosed without routine HIV-2 testing compared with the problems and costs associated with the implementation of HIV-2 testing.

The development of antibodies is similar in HIV-1 and HIV-2. Antibodies generally become detectable within 3 months of infection. Testing for HIV-2 antibodies is available through private physicians or state and local health departments.

Are blood donors tested for HIV-2?

Since 1992, all U.S. blood donations have been tested with a combination HIV-1/HIV-2 enzyme immunoassay test kit that is sensitive to antibodies to both viruses. This testing has demonstrated that HIV-2 infection in blood donors is extremely rare. All donations detected with either HIV-1 or HIV-2 are excluded from any clinical use, and donors are deferred from further donations.

Is the clinical treatment of HIV-2 different from that of HIV-1?

Little is known about the best approach to the clinical treatment and care of patients infected with HIV-2. Given the slower development of immunodeficiency and the limited clinical experience with HIV-2, it is unclear whether antiretroviral therapy significantly slows progression. Not all of the drugs used to treat HIV-1 infection are as effective against HIV-2. In vitro (laboratory) studies suggest that nucleoside analogs are active against HIV-2, though not as active as against HIV-1. Protease inhibitors should be active against HIV-2. However, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are not active against HIV-2. Whether any potential benefits would outweigh the possible adverse effects of treatment is unknown.

WebMD Public Information from the CDC

Today on WebMD

HIV Myth Facts
Slideshow
STD Overview
Article
 
smiling mature man
Article
AIDS retrospective slideshow
Slideshow
 

HIV AIDS Screening
Slideshow
man opening condom wrapper
Quiz
 
HIV AIDS Treatment
Feature
Discrimination Stigma
Feature
 

Treatment Side Effects
Feature
grilled chicken and vegetables
Article
 
obese man standing on scale
Article
cold sore
Article
 

WebMD Special Sections